These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15748086)

  • 1. The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project.
    de Pouvourville G; Ulmann P; Nixon J; Boulenger S; Glanville J; Drummond M
    Pharmacoeconomics; 2005; 23(2):113-20. PubMed ID: 15748086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Network of Health Economic Evaluation Databases (EURO NHEED) Project.
    Nixon J; Ulmann P; Glanville J; Boulenger S; Drummond M; de Pouvourville G
    Eur J Health Econ; 2004 Jun; 5(2):183-7. PubMed ID: 15452755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for completing the EURONHEED transferability information checklists.
    Nixon J; Rice S; Drummond M; Boulenger S; Ulmann P; de Pouvourville G
    Eur J Health Econ; 2009 May; 10(2):157-65. PubMed ID: 18618158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can economic evaluations be made more transferable?
    Boulenger S; Nixon J; Drummond M; Ulmann P; Rice S; de Pouvourville G
    Eur J Health Econ; 2005 Dec; 6(4):334-46. PubMed ID: 16249933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another.
    Goeree R; Burke N; O'Reilly D; Manca A; Blackhouse G; Tarride JE
    Curr Med Res Opin; 2007 Apr; 23(4):671-82. PubMed ID: 17407623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries.
    Franken M; Heintz E; Gerber-Grote A; Raftery J
    Value Health; 2016 Dec; 19(8):951-956. PubMed ID: 27987645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DIABCARE Quality Network in Europe--a model for quality management in chronic diseases.
    Piwernetz K
    Int Clin Psychopharmacol; 2001 Apr; 16 Suppl 3():S5-13. PubMed ID: 11459330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluations in the EURONHEED: a comparative analysis.
    Hutter F; Antoñanzas F
    Pharmacoeconomics; 2009; 27(7):561-70. PubMed ID: 19663527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities.
    Hoffmann C; Stoykova BA; Nixon J; Glanville JM; Misso K; Drummond MF
    Value Health; 2002; 5(2):71-8. PubMed ID: 11918822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing in the European Union: does economic evaluation matter?
    Antoñanzas F; Rodríguez-Ibeas R; Hutter MF; Lorente R; Juárez C; Pinillos M
    Eur J Health Econ; 2012 Oct; 13(5):651-61. PubMed ID: 21598012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
    Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
    Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation databases as an aid to healthcare decision makers and researchers.
    Aguiar-Ibáñez R; Nixon J; Glanville J; Craig D; Rice S; Christie J; Drummond MF
    Expert Rev Pharmacoecon Outcomes Res; 2005 Dec; 5(6):721-32. PubMed ID: 19807614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G8-global healthcare applications project (GHAP) - recommendations for the way into the information society.
    Dietzel G
    Eur J Med Res; 1999 Dec; 4(12):533-6. PubMed ID: 10611059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral arterial obliterative disease. Cost of illness in France.
    Montron A; Guignard E; Pelc A; Comte S
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):51-9. PubMed ID: 10175985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations.
    Lim KK; Koleva-Kolarova R; Fox-Rushby J
    Pharmacoeconomics; 2022 Oct; 40(10):989-1003. PubMed ID: 35907179
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.